Change - Announcement of Appointment::Appointment of Kelvin Tong Wee Chiang as Chief Financial Officer

Issuer & Securities

Issuer/ Manager
QUANTUM HEALTHCARE LIMITED
Securities
QUANTUM HEALTHCARE LIMITED - SGXE57350022 - V8Y
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
29-Jul-2022 03:42:46
Status
New
Announcement Sub Title
Appointment of Kelvin Tong Wee Chiang as Chief Financial Officer
Announcement Reference
SG220729OTHRC70A
Submitted By (Co./ Ind. Name)
Thomas Tan Gim Chua
Designation
Chief Executive Officer
Description (Please provide a detailed description of the event in the box below)
Announcement of the appointment of Kelvin Tong Wee Chiang as Chief Financial Officer.

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). It has not been examined of approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.

Additional Details

Date Of Appointment
30/05/2022
Name Of Person
Kelvin Tong Wee Chiang
Age
44
Country Of Principal Residence
Singapore
The Board's comments on this appointment (including rationale, selection criteria, board diversity considerations, and the search and nomination process)
Pursuant to the completion of the Scheme as announced by QT Vascular Ltd ("QT Vascular") on 28 July 2022, the transfer of listing status from QT Vascular to Quantum Healthcare Limited ("Company") has been completed and the Company will continue to have substantially the same directors and executive officers as those previously in QT Vascular. Please refer to QT Vascular's announcement dated 28 July 2022 and pages 24 to 25 of the scheme document dated 1 June 2022 released by QT Vascular for more details.

The Nominating Committee and the Board of the Company have reviewed and considered the qualifications and experience of Mr Kelvin Tong Wee Chiang, are of the view that Mr Kelvin Tong Wee Chiang has the requisite experience and capability to contribute effectively in the Company, and have approved the appointment of Mr Kelvin Tong Wee Chiang as Chief Financial Officer of the Company.
Whether appointment is executive, and if so, the area of responsibility
Yes. The Chief Financial Officer is responsible for all finance, accounting, tax and risk management functions for the Company and its subsidiaries.
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Chief Financial Officer
Professional qualifications
Chartered Accountant with the Institute of Singapore Chartered Accountants; and Certified Practicing Accountant with CPA Australia.
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
No.
Conflict of interests (including any competing business)
No.
Working experience and occupation(s) during the past 10 years
Chief Financial Officer, QT Vascular Ltd and Quantum Healthcare from 2020 to present
Financial Controller, QT Vascular Ltd from 2014 to 2020
Senior Manager, KPMG LLP from 2000 to 2014
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Yes
Shareholding interest in the listed issuer and its subsidiaries?
Yes
Shareholding Details
12,001,887 Ordinary Shares
150,000 Share Awards under the Quantum Healthcare Restricted Share Plan 2015
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
None.
Present
Director, Asia Dental Group Pte. Ltd.
Director, Trireme Medical (Singapore) Pte. Ltd.
Director, Quattro Vascular Pte. Ltd.
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Any prior experience as a director of an issuer listed on the Exchange?
No
If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange
Not applicable. Mr Kelvin Tong Wee Chiang is not appointed as a director of the Company.
Please provide details of relevant experience and the nominating committee's reasons for not requiring the director to undergo training as prescribed by the Exchange (if applicable)
Not applicable.